Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1984 1
1985 2
1986 2
1988 1
1989 1
1990 3
1991 3
1992 3
1993 4
1994 2
1995 8
1996 4
1997 5
1998 7
1999 7
2000 7
2001 5
2002 6
2003 8
2004 13
2005 11
2006 7
2007 7
2008 16
2009 13
2010 18
2011 31
2012 34
2013 39
2014 29
2015 49
2016 47
2017 62
2018 46
2019 65
2020 55
2021 57
2022 40
2023 47
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

678 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Neuroendocrine Neoplasm"
Page 1
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Nature. 2022 Nov;611(7934):155-160. doi: 10.1038/s41586-022-05368-8. Epub 2022 Oct 26. Nature. 2022. PMID: 36289334 Free PMC article. Clinical Trial.
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma(1). We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV mela …
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresec …
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Robert C, et al. N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166680 Clinical Trial.
BACKGROUND: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. ...CONCLUSIONS: First-line treatment with …
BACKGROUND: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free …
Melanom.
Ugurel S, Gutzmer R. Ugurel S, et al. J Dtsch Dermatol Ges. 2023 Apr;21(4):343-347. doi: 10.1111/ddg.15053. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999586 Review.
Melanoma is a highly aggressive skin tumor nicknamed "black cancer of the skin" because it originates from the pigment-forming cells (melanocytes). The tumors are prone to invasive growth and early lymphogenic and hematogenic metastasis. Known risk factors are UV radiation …
Melanoma is a highly aggressive skin tumor nicknamed "black cancer of the skin" because it originates from the pigment-forming cells (melano …
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Caplin ME, et al. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646366 Free article. Review.
PATIENTS AND METHODS: Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'bronchial neuroendocrine tumors', 'bronchial carcinoid tumors', 'pulmonary carcinoid', 'pulmonary typical/atypical carcin …
PATIENTS AND METHODS: Bibliographical searches were carried out in PubMed for the terms 'pulmonary neuroendocrine tumors', 'br …
Pancreatic neuroendocrine tumors.
Perri G, Prakash LR, Katz MHG. Perri G, et al. Curr Opin Gastroenterol. 2019 Sep;35(5):468-477. doi: 10.1097/MOG.0000000000000571. Curr Opin Gastroenterol. 2019. PMID: 31306159 Review.
PURPOSE OF REVIEW: Pancreatic neuroendocrine tumors (pNETs) are a rare, heterogeneous group of pancreatic neoplasms with a wide range of malignant potential. They may manifest as noninfiltrative, slow-growing tumors, locally invasive masses, or even swiftly m …
PURPOSE OF REVIEW: Pancreatic neuroendocrine tumors (pNETs) are a rare, heterogeneous group of pancreatic neoplasms with a wid …
Nivolumab in melanoma.
Specenier P. Specenier P. Expert Rev Anticancer Ther. 2016 Dec;16(12):1247-1261. doi: 10.1080/14737140.2016.1249856. Epub 2016 Nov 7. Expert Rev Anticancer Ther. 2016. PMID: 27776441 Review.
The addition ipilimumab to nivolumab is associated with a higher response rate and a better PFS, particularly in patients with PD-L1 negative tumors, albeit at the cost of an increase in grade 3-4 adverse event rate. Definitive survival data on this combination are pending …
The addition ipilimumab to nivolumab is associated with a higher response rate and a better PFS, particularly in patients with PD-L1 negativ …
Neuroendocrine neoplasm of the gallbladder: Clinical features, surgical efficacy, and prognosis.
Wu X, Li B, Hong T, Liu W, He X, Zheng C. Wu X, et al. Cancer Med. 2023 May;12(10):11344-11350. doi: 10.1002/cam4.5846. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36952352 Free PMC article.
BACKGROUND: Neuroendocrine neoplasm (NEN) of the gallbladder is rare. It is usually asymptomatic and occurs in older adults. ...Surgery is the first choice of treatment for this rare disease. The prognosis of gallbladder NEN is generally poor. Patients with r …
BACKGROUND: Neuroendocrine neoplasm (NEN) of the gallbladder is rare. It is usually asymptomatic and occurs in older adults. . …
Metastatic liver tumors.
McCarter MD, Fong Y. McCarter MD, et al. Semin Surg Oncol. 2000 Sep-Oct;19(2):177-88. doi: 10.1002/1098-2388(200009)19:2<177::aid-ssu9>3.0.co;2-s. Semin Surg Oncol. 2000. PMID: 11126381 Review.
The data regarding liver resection for other metastatic tumor types are less clear. However, resection for selected tumors, such as neuroendocrine and renal cell, can provide durable palliation and/or cure. ...The role of adjuvant regional and systemic chemotherapy …
The data regarding liver resection for other metastatic tumor types are less clear. However, resection for selected tumors, such as …
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Dummer R, et al. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. Lancet Oncol. 2017. PMID: 28284557 Clinical Trial.
METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on …
METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresect …
Radiopharmaceuticals for Neuroendocrine Tumors.
Chin RI, Wu FS, Menda Y, Kim H. Chin RI, et al. Semin Radiat Oncol. 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. Semin Radiat Oncol. 2021. PMID: 33246637 Review.
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. ...Similarly, data from the multicenter, phase II Study IB12B led to the approval of meta-[(131)I]Iodo-Benzyl-Guanidine ((I31)I-MIBG) for …
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the bod …
678 results